Synthesis of four-membered ring spiro-β-lactams by epoxide ring-opening

European Journal of Organic Chemistry

Volumn , Issue 19, 2007, Pages 3199-3205

  Benfatti, Fides ^a   Cardillo, Giuliana ^a   Gentilucci, Luca ^a   Tolomelli, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Lactams; Oxygen heterocycles; Regioselectivity; Ring opening; Spiro compounds

Indexed keywords

EID: 34447321351     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200601110     Document Type: Article

References (57)

1. a) B. K. Hubbard, C. T. Walsh, Angew. Chem. Int. Ed. 2003, 42, 730-765;
2. b) R. Nau, A. Eiffert, Clin. Microbiol. Rev. 2002, 15, 95-110;
3. c) O. A. Mascaretti, G. O. Danelon, M. Laborde, E. G. Mata, E. L. Setti, Curr. Pharm. Des. 1999, 5, 939-953;
4. d) M. Kidwai, P. Sapra, K. R. Bhushan, Curr. Med. Chem. 1999, 3, 195-215;
5. e) J. M. T. Hamilton-Miller, J. Antimicrob. Chemother. 1999, 44, 729-734;
6. f) E. L. Setti, R. G. Micetich, Curr. Med. Chem. 1998, 5, 101-114;
7. g) R. Southgate, C. Branch, S. Coulton, E. Hunt, in Recent Progress in the Chemical Synthesis of Antibiotics and Related Microbial Products (Ed.: G. Lukacs), Springer-Verlag, Berlin, 1993, vol. 2, p. 621;
8. h) Chemistry and Biology of β-Lactam Antibiotics (Eds.: R. B. Morin, M. Gorman), Academic Press, New York, 1982; vol. 1-3.
9. a) E. L. Setti, D. Davis, J. W. Janc, D. A. Jeffery, H. Cheung, W. Yu, Bioorg Med. Chem. Lett. 2005, 15, 1529-1534;
10. b) E. L. Setti, D. Davis, Bioorg. Med. Chem. Lett. 2003, 13, 2051-2053;
11. c) R. Annunziata, M. Benaglia, M. Cinquini, F. Cozzi, A. Puglisi, Bioorg. Med. Chem. 2002, 10, 1813-1818;
12. d) T. M. Haley, S. J. Angier, A. D. Borthwick, R. Singh, R. G. Micetich, Drugs 2000, 3, 512-517;
13. e) M. I. Page, A. P. Laws, Tetrahedron 2000, 56, 5631-5638;
14. f) P. R. Bonneau, F. Hasani, C. Plouffe, E. Malenfant, S. R. LaPlante, I. Guse, W. W. Ogilvie, R. Plante, W. C. Davidson, J. L. Hopkins, M. M. Morelock, M. G. Cordingley, R. Deziel, J. Am. Chem. Soc. 1999, 121, 2965-2973;
15. g) S. R. La Plante, P. R. Bonneau, N. Aubry, D. R. Cameron, R. Deziel, C. Grand-Maitre, C. Plouffe, L. Tong, S. H. Kawai, J. Am. Chem. Soc. 1999, 121, 2974-2986;
16. h) W. W. Ogilvie, C. Yoakim, F. Do, B. Hache, L. Lagace, J. Naud, J. A. O'Meara, R. Deziel, Bioorg. Med. Chem. 1999, 7, 1521-1531;
17. i) J. Pitlik, C. A. Townsend, Bioorg. Med. Chem. Lett. 1997, 7, 3129-3134;
18. j) O. A. Mascaretti, C. E. Boschetti, G. O. Danelon, E. G. Mata, A. A. Roveri, Curr. Med. Chem. 1995, 1, 441-470;
19. k) W. T. Han, A. K. Trehan, J. K. K. Wright, M. E. Federici, S. M. Seiler, N. A. Meanwell, Bioorg. Med. Chem. 1995, 3, 1123-1143.
20. G. Gerona-Navarro, M. J. Perez de Vega, M. T. Garcia-Lopez, G. Andrei, R. Snoeck, J. Balzarini, E. De Clercq, R. Gonzalez-Muniz, Bioorg. Med. Chem. Lett. 2004, 14, 2253-2256.
21. a) E. Alonso, F. Lopez-Ortiz, C. del Pozo, E. Peralta, A. Marias, J. Gonzalez, J. Org. Chem. 2001, 66, 6333-6338;
22. b) H. Bitterman, P. Gmeiner, J. Org. Chem. 2006, 71, 97-102.
23. For spiro-lactam-based CAI inhibitors see: a) J. Clader, Curr. Top. Med. Chem. 2005, 5, 243-256;
24. b) T. Kambara, K. Tomioka, J. Org. Chem. 1999, 64, 9282-9285;
25. c) G. Wu, W. Tormos, J. Org. Chem. 1997, 62, 6412-6414;
26. d) B. A. McKittrick, K. Ma, S. Dugar, J. W. Clader, H. Davis Jr, M. Czarniecki, A. T. McPhail, Bioorg. Med. Chem. Lett. 1996, 6, 1947-1950;
27. for non-spiro-lactam-based inhibitors: e) G. S. Singh, Mini-Rev. Med. Chem. 2004, 4, 69-92;
28. f) B. A. McKittrick, K. Ma, K. Huie, N. Yumibe, H. Davis Jr, J. W. Clader, M. Czarniecki, A. T. McPhail, J. Med. Chem. 1998, 41, 752-759;
29. g) D. A. Burnett, M. A. Caplen, H. Davis Jr, R. E. Burrier, J. W. Clader, J. Med. Chem. 1994, 37, 1733-1736.
30. B. Alcaide, P. Almendros, T. Martinez-del Campo, R. Rodriguez-Acebes, Tetrahedron Lett. 2004, 45, 6429-6431.
31. a) C. Bonini, G. Righi, Synthesis 1994, 225-238;
32. b) G. Berti, in Topics in Stereochemistry (Eds.: N. L. Allinger, E. L. Eliel), John Wiley & Sons, New York, 1973, vol. 7, pp. 93-251 and reference cited therein;
33. c) T. J. Sommer, Synthesis 2004, 161-201;
34. d) J. G. Smith, Synthesis 1984, 629-656;
35. e) M. Shimizu, A. Yoshida, T. Fujisawa, Synlett 1992, 204-206;
36. f) N. Iranpoor, M. I. Baltork, Synth. Commun. 1990, 20, 2789-2797;
37. g) S. C. Bergmeier, Tetrahedron 2000, 56, 2561-2576.
38. a) D. J. Ager, M. B. East, in Asymmetric Synthetic Methodology 1995, CRC-Press, New York, chapter 11;
39. b) R. W. Hoffmann, Chem. Rev. 1989, 89, 1841-1860;
40. c) C. W. Still, A. G. Romero, J. Am. Chem. Soc. 1986, 108, 2105-2106.
41. a) F. Benfatti, G. Cardillo, S. Fabbroni, L. Gentilucci, R. Perciaccante, F. Piccinelli, A. Tolomelli, Synthesis 2005, 61-70;
42. b) F. Benfatti, G. Cardillo, S. Fabbroni, L. Gentilucci, R. Perciaccante, A. Tolomelli, Synlett 2005, 2204-2208.
43. a) S. Kobayashi, T. Busujima, S. Nagayama, Chem. Eur. J. 2000, 6, 3491-3494;
44. b) D. Ferraris, W. J. Drury III, C. Cox, T. Lectka, J. Org. Chem. 1998, 63, 4568-4569;
45. c) R. G. Pearson, J. Am. Chem. Soc. 1963, 85, 3533-3539;
46. d) F. J. Casado-Bellver, M. E. Gonzalez-Rosende, A. Asensio, J. M. Jordà-Gregori, A. Alvarez-Sorolla, J. Sepulveda-Arques, M. Orena, G. Galeazzi, J. Chem. Soc., Perkin Trans. 1 2002, 1650-1654;
47. e) K. Oh, D. Chesire, P. J. Parson, Synlett 2005, 1630-1632.
48. J. M. Coxon, M. P. Hartshorn, W. H. Swallow, Aust. J. Chem. 1973, 26, 2521-2526.
49. Conformations were minimized with the Amber 8.0-Gaussian 03 package; NOESY-1D-DPFGSE is a double-pulsed-field-gradient-spin-echo pulse sequence experiment, see J. Stonehouse, P. Adell, J. Keeler, A. J. Shaka, J. Am. Chem. Soc. 1994, 116, 6037-6038.
50. Chemical shifts of epoxides 2 and 6 and products 3, 4, 7 and 8 are reported in Tables A, B, and C in the Supporting Information.
51. a) T. Masamune, M. Ono, S. Sato, A. Murai, Tetrahedron Lett. 1978, 19, 371-374;
52. b) J.-P. Bats, J. Moulines, P. Picard, D. Leclercq, Tetrahedron Lett. 1980, 21, 3051-3054;
53. c) J.-P. Bats, J. Moulines, P. Picard, D. Leclercq, Tetrahedron 1982, 38, 2139-2146;
54. d) T. Fukuyama, B. Vranesic, D. P. Negri, Y. Kishi, Tetrahedron Lett. 1978, 31, 2741-2744.
55. Initial geometry optimizations were performed with Gaussian 03 - DFT B3LYP/STO-3G2, after which MM geometry optimization with the GAFF (Generalized Amber Force Field) in the "sander" module of Amber 8.0 was applied.
56. a) G. Stork, J. F. Cohen, J. Am. Chem. Soc. 1974, 96, 5268-5269;
57. b) G. Stork, L. D. Cama, D. R. Coulson, J. Am. Chem. Soc. 1974, 96, 5270-5272.